Skip to main content
. 2018 May 25;37:109. doi: 10.1186/s13046-018-0752-0

Table 2.

Half maximal inhibitory concentrations (IC50) of anti-cancer drugs in AMC-H1 and AMC-H2 primary HCC

IC50(μM) IC50ER
AMC-H1 AMC-H2
5-FU 2.05 1.71 1.198830409
Cisplatin 4.91 3.71 1.323450135
Taxol 0.125 0.127 0.984251969
Sorafenib 7.92 21.08 0.375711575

aIC50ER: IC50 with enhancement ratio (AMC-H1/AMC-H2)